Sugi Predict

Sugi Predict / Compounds / SCHEMBL17632152

SCHEMBL17632152

SCHEMBL17632152

CC(C)(C)OC(=O)N1CCC(C#N)(C(=O)O)C1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CTSK P43235 1/20 0.40
▸ USP30 Q70CQ3 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SCD5 Q86SK9 1/20 0.38
▸ JAK2 O60674 3/20 0.38
▸ JAK1 P23458 3/20 0.38
▸ CYP11B2 P19099 1/20 0.37
▸ GPR119 Q8TDV5 2/20 0.37
▸ RORC P51449 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388054 0.91 USP2 (0.46) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL13957351 0.88 USP2 (0.41) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL17632316 0.82 CTSK (0.39) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL3105218 0.81 USP2 (0.45) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL22978686 0.80 MEN1 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL5751932 0.79 USP2 (0.44) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL28587335 0.79 VNN1 (0.46) USP2SMN1; SMN2CTSKUSP30MEN1
SCHEMBL28604412 0.79 VNN1 (0.46) USP2SMN1; SMN2CTSKUSP30MEN1
SCHEMBL2378427 0.79 USP2 (0.42) USP2SMN1; SMN2CTSKUSP30MEN1
SCHEMBL13993957 0.79 USP2 (0.42) USP2SMN1; SMN2CTSKUSP30MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 — — CN disclosed
US-11584738-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-02-21 — — US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
US-20180162852-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED 2018-06-14 — — US disclosed
US-20180162852-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED 2018-06-14 — — US disclosed
US-9926307-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2018-03-27 — — US disclosed
US-9926307-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2018-03-27 — — US disclosed
US-9926307-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2018-03-27 — — US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 — — US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 — — US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 — — US disclosed
EP-3197883-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2017-08-02 — — EP disclosed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584738-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 USP2 3940/4885SMN1; SMN2 4659/4885CTSK 1419/4885
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 USP2 17/4885SMN1; SMN2 3529/4885CTSK 1201/4885
US-20180162852-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 USP2 14/4885SMN1; SMN2 3600/4885CTSK 1237/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 USP2 17/4885SMN1; SMN2 3529/4885CTSK 1201/4885
US-20170247365-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 USP2 14/4885SMN1; SMN2 3600/4885CTSK 1237/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 USP2 14/4885SMN1; SMN2 3600/4885CTSK 1237/4885
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 USP2 3940/4885SMN1; SMN2 4659/4885CTSK 1419/4885
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 USP2 3940/4885SMN1; SMN2 4659/4885CTSK 1419/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 USP2 3940/4885SMN1; SMN2 4659/4885CTSK 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.